Episode 371: TROPiCS-04 Results From ESMO Asia

Jonathan Rosenberg of Memorial Sloan Kettering joins Brian and Tom to discuss the phase 3 TROPiCS-04 trial and new updates on its efficacy and toxicity signals.
The study examined sacituzumab govitecan versus single-agent chemotherapy in patients with mUC who had previously received platinum-containing chemotherapy and anti-PD-L1 therapy.